Home News About us Comitato scientifico Iscriviti Utenti Etica Contenuti Guida Faq Stage Contatti ☰
Logo Pharmamedix
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Fluvoxamina

Dumirox, Maveral e altri

Bibliografia - Quali fonti bibliografiche per Fluvoxamina?

  1. Alderman C.P., Frith P.A., Aust. N. Z. J. Psychiatry, 1999 (33 (1), 99.

  2. Altamura A.C. et al., Expert. Opin. Drug Metab. Toxicol., 2015, 11 (4), 649.

  3. Andrisano C. et al., Int. Clin. Psychopharmacol. 2013, 28 (1), 33.

  4. Appolinario J.C., McElroy S.L., Curr. Drug Targets, 2004, 5 (3), 301.

  5. Asakura S. et al., Drugs real World Outcomes, 2014, 1 (1), 7.

  6. Azuma J. et al., Eur. J. Clin. Pharmacol., 2012, 68 (1), 29.

  7. Becker C. et al., Eur. J. Clin. Pharmacol., 2020, 76 (9), 1329.

  8. Berkman N.D. et al., Effective Health Care Program – Management and Outcomes of Binge Eating Disorder, Rockville (MD): Agency for healthcare Research and Quality (US), 2015, Dec., Report No.: 15(16)-EHC030-EF.

  9. Beyer C. et al., Depress. Anxiety, 2017, 34 (12), 1134.

  10. Black D.W. et al., 2000, 12 (4), 205.

  11. Blanco C. et al., Ann. Clin. Psychiatry., 2002, 14 (1), 9.

  12. Bondolfi G. et al., Psychopharmacology (Berl), 1996, 128 (4), 421.

  13. Bramante C.T. et al., NEJM, 2022, 387 (7), 599.

  14. Britz H. et al., CPT Pharmacometrics Syst. Pharmacol., 2019, 8 (5), 296.

  15. Bykov K. et al., Am. J. Cardiol., 2017, 119 (4), 651.

  16. Carter W.P. et al., Int. J. Eat Disord., 2003, 34 Suppl., S74.

  17. Cipriani A. et al., lancet, 2018, 391 (10128, 1357.

  18. Chiu C.C. et al., J. Clin. Pharmacol., 2004, 44 (12), 1385.

  19. Choi Y-J., J. Am. Acad. Nurse Pract., 2009, 21 (4), 207.

  20. Chou P.H. et al., J. Affect. Disord., 2017, 215, 237.

  21. Chung S. K. et al., Yonsei Med. J., 2009, 50 (3), 441.

  22. Christensen M. et al., Clin. Pharmacol. Ther., 2002, 71 (3), 141.

  23. Conus P. et al., Pharmacopsychiatry, 1996, 29 (3), 108.

  24. Cooper W.O. et al., Pediatrics, 2014, 133 (2), 204.

  25. Culm-Merdek K.E. et al., Br. J. Clin. Pharmacol., 2005, 60 (5), 486.

  26. Dalhoff K. et al., Eur. J. Clin. Pharmacol., 1991, 41 (4), 351.

  27. Damkier P. et al., Eur. J. Clin. Pharmacol., 1999, 55 (6), 451.

  28. Dannon P.N. et al., Clin Neuropharmacol., 2005, 28 (1), 6.

  29. Davidson J.R. et al., J. Clin. Psychopharmacol., 1998, 18 (1), 93.

  30. de Boer M. et al., Psychother. Psychosom., 1992, 57 (4), 158.

  31. De Picker L. et al., Psychosomatics, 2014, 55 (6), 536.

  32. de Weger V.A. et al., Cancer Chemother. Pharmacol., 2018, 81 (1), 73.

  33. Demers J.C., Malone M., Ann. Pharmacother., 2001, 35 (10), 1217.

  34. Deng J. et al., Clin. Microbiol. Infect., 2023, doi:10.1016/j.cmi.2023.01.010

  35. Du Y. et al., Asian J. Psychiatr., 2021, 60, 102664.

  36. Edinoff A.N. et al., Neurol. Int., 2021, 13 (3), 387.

  37. Escalona R. et al., Depress. Anxiety, 2002, 15 (1), 29.

  38. Eugene A.R., Peerj., 2019, 7, e7860.

  39. Fichter M.M. et al., J. Clin. Psychopharmacol., 1996, 16, 9.

  40. Fleishaker J.C., Hulst L.K., Eur. J. Clin. Pharmacol., 1994, 46 (1), 35.

  41. Fritze J. et al., Acta Psychiatr. Scand., 1991, 84 (6), 583.

  42. Fukasawa T. et al., Ther. Drug Monit., 2006, 28 (3), 308.

  43. Gabriel A., Case Rep. Med., 2009, 2009, 585193.

  44. Garnier R. et al., J. Int. Med. Res., 1993, 21 (4), 197.

  45. Gentile S., Arch. Womens Ment. Health, 2006, 9 (3), 158.

  46. GheldiuA.M. et al., J. Pharm. Pharm. Sci., 2017, 20, 68.

  47. Gorman J. R. et al., J. Hum. Lact., 2012, 28 (2), 181.

  48. Granfors M.T. et al., Clin. Pharmacol. Ther., 2004, 75 (4), 331.

  49. Grzeskowiak L.E. et al., Acta Obstet, Gynecol. Scand., 2022, 101 (3), 344.

  50. Hartter S. et al., Ther. Drug Monit., 1998, 20 (4), 446.

  51. Hartter S. et al., Pharmacopsychiatry, 1998a, 31 (5), 199.

  52. Hartter S. et al., Clin. Pharmacol. Ther., 2000, 67 (1), 1.

  53. Hartter S. et al., J. Clin. Psychopharmacol., 2001, 21 (2), 167.

  54. Hendrick V. et al., Br. J. Psychiatry, 2001, 17, 163.

  55. Hendrick V. et al., J. Clin. Psychiatry., 2003, 64 (4), 410.

  56. Hindmarch I., Hashimoto K., Hum. Psychopharmacol., 2010, 25 (3), 193.

  57. Hollander E. et al., Am. J. psychiatry, 1998, 155 (12), 1781.

  58. Hollander E. et al., Biol. Psychiatry, 2000, 47 (9), 813.

  59. Hudson J.I. et al., Am. J. Psychiatry, 1998, 155 (12), 1756.

  60. Ikenouchi A. et al., Psychiatry Clin. Neurosci., 2007, 61 (4), 452.

  61. Irons J., Neuropsychiatr. Dis. Treat., 2005, 1 (4), 289.

  62. Isohanni M.H. et al., Basic Clin. Pharmacol. Toxicol., 2006, 99 (2), 168.

  63. Jacob S., Spinler S.A., Ann. Pharmacother., 2006, 40 (9), 1618.

  64. Jokinen M.J. et al., Anesth. Analog., 2000, 91 (5), 1207.

  65. Juurlink D.N. et al., Br. J. Clin. Pharmacol., 2005, 59 (1), 102.

  66. Kadokura T. et al., Eur. J. Clin. Pharmacol., 2008, 64 (7), 691.

  67. Kamo T. et al., Psychiatry Clin. Neurosci., 2004, 58 (2), 133.

  68. Kanacher T. et al., Pharmaceutics., 2020, 12 (12), 1191.

  69. Karaküçük Y. et al., Psychiatry Clin. Psychopharmacol., 2019, 29 (4), 387.

  70. Khano E., Entezari-Maleki T., Molecular Psychiatry, 2022, 27, 3562.

  71. Kieviet N. et al., Acta Pediatr., 2015, 104, 384.

  72. Kishi T. et al., Mol. Psychiatry, 2023, 28 (1), 402.

  73. Kotapati V.P. et al., Front. Psychiatry, 2019, 10, 523.

  74. Krasowska D. et al., J. Am. Acad. Dermatol., 2007, 56 (5), 848.

  75. Kristensen J.H. et al., J. Hum. Lact., 2002, 18 (2), 139

  76. Kunii T. et al., Ther. Drug. Monit., 2005, 27 (3), 349.

  77. Kusumoto M. et al., Clin. Pharmacol. Ther., 2001, 69 (3), 104.

  78. Labbellarte M. et al., J. am. Acad. Child Adolesc. Psychiatry, 2004, 43 (12), 1497.

  79. Lactmed, 2022 18 April https://www.ncbi.nlm.nih.gov/books/NBK501187/

  80. Lamberg T.S. et al., Eur. J. Clin. Pharmacol., 1998, 54 (9-10), 761.

  81. Lee A. et al., Am. J. Obstet. Gynecol., 2004, 190 (1), 218.

  82. Lee S.Y. et al., Ther. Adv. Chronic Dis., 2022, doi: 10.1177/20406223221098114.

  83. Leggett C. et al., J. Hum. Lact., 2017, 33 (4), 701.

  84. Lenze E.J. et al., 2020, JAMA, 324 (22), 2292.

  85. Limke K.K. et al., Ann. Pharmacoher., 2002, 36 (12), 1890.

  86. Liu X. Et al., Medicine (Baltimore), 2018, 97 (28), e11547.

  87. Narita H. et al., Eur. J. Pharmacol., 1996, 307, 117.

  88. Marcinko D, Karlovic D., Psychiatr. Danub., 2005, 17 (1-2), 97.

  89. Marcinko D. et al., Prog. Neuropsychopharmacol. Biol. Pasychiatry, 2006, 30 (8), 1542.

  90. Marmar C.R. et al., J. Clin. Psychiatry, 57 Suppl. 8, 66.

  91. Marshall A.M. et al., J. Clin. Endocrinol. Metab., 2010, 95 (2), 837.

  92. Martinelli V. et al., Br. J. Clin. Pharmacol., 1993, 36 (6), 615.

  93. Milano W. et al., Adv. Ther., 2005, 22 (3), 278.

  94. Miljkovic B.R. et al., Int. Clin. Psychopharmacol., 1997, 12 (4), 207.

  95. Mizokami F. et al., J. Dermatol., 2016, 43 (4), 436.

  96. Montastruc G. et al., Br. J. Clin. Pharmacol., 2010, 69 (3), 287.

  97. NEJM, 2001, 344 (17), 1279.

  98. Neylan T.C. et al., J. Trauma Stress, 2001, 14 (3), 461.

  99. Niemi M. et al., Clin. Pharmacol. Ther., 2001, 69 (4), 194.

  100. Ninan P.T. et al., J. Clin. Psychopharmacol., 2000, 20 (3), 362.

  101. Ochs H.R. et al., J. Clin. Pharmacol., 1989, 29 (1), 91.

  102. Olkkola K.T. et al., Anesth. Analg., 2005, 100 (5), 1352.

  103. Orlando R. et al., Br. J. Clin. Pharmacol., 2010, 69 (3), 279.

  104. Pallanti S. et al., CNS Spectr., 2006, 11 (12), 956.

  105. Perucca E. et al., Clin. Pharmacokinet., 1994, 27 (3), 175.

  106. Perugi G. et al., Int. Clin. Psychopharmacol., 1996, 11 (4), 247.

  107. Phillips K.A. et al., Psychiatr. Q., 2004, 75 (4), 309.

  108. Phillips K.A. et al., J. Clin. Psychiatry, 1998, 59 (4), 165.

  109. Piccinelli M. et al., Br. J. psychiatry, 1995, 166 (4), 424.

  110. Polcwiartek C., Nielsen J., Psychopharmacology (Berl), 2016, 233 (5), 741.

  111. Reis G. et al., Lancet Glob Health, 2022, 10 (1), e42.

  112. Ricca V. et al., Psychother. Psychosom., 2001, 70 (6), 298.

  113. Santarsieri D., Schwart T.L., Drugs Context, 2015, 4, 212290.

  114. Saruwatari J.et al., J. Clin. Psychopharmacol., 2012, 32 (2), 195.

  115. Seemuller F. et al., Int. J. Neuropsychopharmacol., 2009, 12 (2), 181.

  116. Seo H. et al., Infect. Chemother., 2022, 54 (1), 102.

  117. Skapinakis P. et al., Lancet Psychiatry, 2016, 3 (8), 730.

  118. Spigset O., et al., Clin. Pharmacol. Ther., 1995, 58 (4), 399.

  119. Spigset O. et al., Eur. J. Clin. Pharmacol., 2001, 57 (9), 653.

  120. Spina E et al., Clin Ther., 2008, 30, 1206

  121. Spina E. et al., Ther. Drug Monit., 1993, 15 (3), 243.

  122. Spina E. et al., Ther. Drug Monit., 1993a, 15 (3), 247.

  123. Spina E. et al., CNS Drugs, 2012, 26, 39.

  124. Sproule B.A. et al., Clin. Pharmacokinet., 1997, 33 (6), 454.

  125. Stahl S.M., CNS Spectr., 2005, 10 (4), 319.

  126. Suzuki Y. et al., J. Psychopharmacol., 2011, 25 (7), 908.

  127. Tao Y. et al., J. Psychiatr. Res., 2022, 148, 95.

  128. Todor I. et al., Pharmacology, 2017, 99 (1-2), 84.

  129. Trenque T. et al., Drug Saf., 2011, 34 (12), 1161.

  130. Tucker P. et al., J. Clin. Psychopharmacol., 2000, 20 (3), 367.

  131. van Harten J. et al., Clin. Pharmacol. Ther., 1992, 52 (4), 427.

  132. van Harten J. et al., Clin. Pharmacokinet., 1993, 24 (2), 177.

  133. van Harten J., Clin. Pharmacokinet., 1995, 29 Suppl. 1, 1.

  134. Von Bahr C. et al., Eur. J. Clin. Pharmacol., 2000, 56 (2), 123.

  135. von Knorring A.L. et al., J. Clin. Psychopharmacol., 2006, 26 (3), 311.

  136. von Richter O. et al., Clin. Pharmacother., 2007, 46 (7), 613.

  137. Venkatesh K.K. et al., J. Perinatol., 2017, 37 (9), 1003.

  138. Vezmar S.et al., J. Pharmacol. Sci., 2009, 110 (1), 98.

  139. Vlase L. et al., Clin. Exp. Pharmacol. Physiol., 2012, 369 (1), 9.

  140. Uguz F., J. Hum. Lact., 2015, 31 (3), 371.

  141. Uno T. et al., Br. J. Clin. Pharmacol., 2006, 61 (3), 309.

  142. Yap K.B., Low S.T., Singapore Med. J., 1999,40 (7), 480.

  143. Yasui-Furukori N. et al., J. Clin. Pharmacol., 2004, 44 (11), 1223.

  144. Yasui-Furukori N., et al., Ther. Drug Monit., 2016, 38 (4), 483.

  145. Yoshida K. et al., Br. J. Clin. Pharmacol., 1997, 44 (2), 210.

  146. Yu L-S. et al., Chem. Biol. Interact., 2003, 146 (3), 263.

  147. Walkup J. et al., J. Child Adolesc. Psychopharmacol., 2002, 12 (3), 175.

  148. Wang C-Y et al., J. Clin. Pharmacol., 2004, 44 (7), 785.

  149. Watanabe J. et al., Ther. Drug Monit., 2008, 30 (6), 705.

  150. Williams T. et al., Acta Neuropsychiatr., 2020, 32 (4), 169.

  151. World Health Organization – WHO, Living guidance for clinical management of COVID-19, 2021 https://www.who.int/publications/i/item/WHO-2019-nCoV-clinical-2021-2

  152. Zhang F. et al., Eur. J. Hosp. Pharm., 2022, doi: 10.1136/ejhpharm-2022-003533.